Argenx announces Public Offering of $231 Million

argenx (Euronext & NASDAQ: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of its public offering in the United States (the Offering) with anticipated gross proceeds totaling approximately $231 million from the sale of 4,440,000 American Depository Shares (ADSs), at a price to the public of $52.00 per ADS. argenx increased the Offering from the initially filed offering size of $150 million.

Argenx allows underwriters a choice to purchase up to an additional 666,000 Ads, which represents 15% of the ADSs sold in the offering.  This option can be exercised within 30 days of December 13th, 2017.  The offer is anticipated to close on December 18th, 2017.

Cowen and Piper Jaffray & Co. are acting as joint bookrunning managers for the Offering, and JMP Securities and Wedbush PacGrow are acting as co-managers. Kempen & Co is argenx’s advisor in connection with the Offering.

A registration statement relating to and describing the terms of the Offering has been filed with, and was declared effective by, the U.S. Securities and Exchange Commission (SEC) on December 13, 2017.

Leave a Comment